NasdaqGM:OMERPharmaceuticals
Assessing Omeros (OMER) Valuation After YARTEMLEA’s FDA Approval And Planned US Launch
Omeros (OMER) drew fresh investor attention after the U.S. Food and Drug Administration approved YARTEMLEA for hematopoietic stem cell transplant associated thrombotic microangiopathy, and the company is preparing a U.S. launch and related reimbursement infrastructure.
See our latest analysis for Omeros.
The FDA approval appears to be the main backdrop for recent price action, with a 30 day share price return of 50.97% and a 90 day share price return of 268.92%. Meanwhile, the 1 year total...